Enanta Pharmaceuticals, Inc.

The momentum for this stock is not very good. Enanta Pharmaceuticals, Inc. has good growth characteristics. Enanta Pharmaceuticals, Inc. is not very popular among insiders. Enanta Pharmaceuticals, Inc. is a mediocre stock to choose.
Log in to see more information.
Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. It engages...
ENTA Fundamental Data by TradingView

News

Acadian Asset Management LLC Has $11.01 Million Holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)
Acadian Asset Management LLC Has $11.01 Million Holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Ticker Report Acadian Asset Management LLC lessened its position in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 0.5% in the second quarter, according to the company in its most recent...\n more…

Insiders Relieved After Selling Enanta Pharmaceuticals With 10% Price Dip
Insiders Relieved After Selling Enanta Pharmaceuticals With 10% Price Dip

Simply Wall St Over the past year, insiders sold US$325k worth of Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ) stock at an average...\n more…

Enanta Pharmaceuticals to Participate in Investor Conferences in September
Enanta Pharmaceuticals to Participate in Investor Conferences in September

Business Wire Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that members of...\n more…

Brokerages Set Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Price Target at $19.00
Brokerages Set Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Price Target at $19.00

Zolmax Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the six ratings firms that are currently covering the company, MarketBeat...\n more…

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Ticker Report Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) has been given an average rating of "Moderate Buy" by the six brokerages that are presently covering the stock, MarketBeat.com reports...\n more…

Enanta Pharmaceuticals (NASDAQ:ENTA) Share Price Passes Below Two Hundred Day Moving Average of $13.75
Enanta Pharmaceuticals (NASDAQ:ENTA) Share Price Passes Below Two Hundred Day Moving Average of $13.75

Zolmax Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report)'s stock price passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of...\n more…